ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM)

Andrew Lassman; Stephanie Pugh; Tony Wang; Kenneth Aldape; Hui Gan; Matthias Preusser; Michael Vogelbaum; Erik Sulman; Minhee Won; Peixin Zhang; Golnaz Moazami; Marian Macsai; Mark Gilbert; Earle Bain; Vincent Blot; Peter Ansell; Suvajit Samanta; Madan Kundu; Clemens Seidel; Filip De Vos; Sigmund Hsu; Andrés Cardona; Giuseppe Lombardi; Dmitry Bentsion; Richard Peterson; Craig Gedye; Christine Lebrun-Frénay; Antje Wick; Walter Curran; Minesh Mehta

doi:10.1093/neuonc/noz175.064

ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM)

Andrew Lassman, Stephanie Pugh, Tony Wang, Kenneth Aldape, Hui Gan, Matthias Preusser, Michael Vogelbaum, Erik Sulman, Minhee Won, Peixin Zhang, Golnaz Moazami, Marian Macsai, Mark Gilbert, Earle Bain, Vincent Blot, Peter Ansell, Suvajit Samanta, Madan Kundu, Clemens Seidel, Filip De VosSigmund Hsu, Andrés Cardona, Giuseppe Lombardi, Dmitry Bentsion, Richard Peterson, Craig Gedye, Christine Lebrun-Frénay, Antje Wick, Walter Curran, Minesh Mehta

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
DOIs	https://doi.org/10.1093/neuonc/noz175.064
State	Published - Nov 11 2019
Event	Neuro-oncology - Duration: Nov 11 2019 → …

Conference

Conference	Neuro-oncology
Period	11/11/19 → …

Disciplines

Oncology
Internal Medicine
Medicine and Health Sciences
Immunology and Infectious Disease

Access to Document

10.1093/neuonc/noz175.064License: Unspecified

Cite this

Lassman, A., Pugh, S., Wang, T., Aldape, K., Gan, H., Preusser, M., Vogelbaum, M., Sulman, E., Won, M., Zhang, P., Moazami, G., Macsai, M., Gilbert, M., Bain, E., Blot, V., Ansell, P., Samanta, S., Kundu, M., Seidel, C., ... Mehta, M. (2019). ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM). Neuro-oncology. https://doi.org/10.1093/neuonc/noz175.064

Lassman, A, Pugh, S, Wang, T, Aldape, K, Gan, H, Preusser, M, Vogelbaum, M, Sulman, E, Won, M, Zhang, P, Moazami, G, Macsai, M, Gilbert, M, Bain, E, Blot, V, Ansell, P, Samanta, S, Kundu, M, Seidel, C, De Vos, F, Hsu, S, Cardona, A, Lombardi, G, Bentsion, D, Peterson, R, Gedye, C, Lebrun-Frénay, C, Wick, A, Curran, W & Mehta, M 2019, 'ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM)', Neuro-oncology, 11/11/19. https://doi.org/10.1093/neuonc/noz175.064

@conference{1ce7ff57824748d49dd0351d30dd7e9e,

title = "ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM)",

author = "Andrew Lassman and Stephanie Pugh and Tony Wang and Kenneth Aldape and Hui Gan and Matthias Preusser and Michael Vogelbaum and Erik Sulman and Minhee Won and Peixin Zhang and Golnaz Moazami and Marian Macsai and Mark Gilbert and Earle Bain and Vincent Blot and Peter Ansell and Suvajit Samanta and Madan Kundu and Clemens Seidel and \{De Vos\}, Filip and Sigmund Hsu and Andr{\'e}s Cardona and Giuseppe Lombardi and Dmitry Bentsion and Richard Peterson and Craig Gedye and Christine Lebrun-Fr{\'e}nay and Antje Wick and Walter Curran and Minesh Mehta",

note = "You do not currently have access to this article. Subscription prices and ordering ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM) - 24 Hours access; Neuro-oncology ; Conference date: 11-11-2019",

year = "2019",

month = nov,

day = "11",

doi = "10.1093/neuonc/noz175.064",

language = "American English",

}

TY - CONF

T1 - ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM)

AU - Lassman, Andrew

AU - Pugh, Stephanie

AU - Wang, Tony

AU - Aldape, Kenneth

AU - Gan, Hui

AU - Preusser, Matthias

AU - Vogelbaum, Michael

AU - Sulman, Erik

AU - Won, Minhee

AU - Zhang, Peixin

AU - Moazami, Golnaz

AU - Macsai, Marian

AU - Gilbert, Mark

AU - Bain, Earle

AU - Blot, Vincent

AU - Ansell, Peter

AU - Samanta, Suvajit

AU - Kundu, Madan

AU - Seidel, Clemens

AU - De Vos, Filip

AU - Hsu, Sigmund

AU - Cardona, Andrés

AU - Lombardi, Giuseppe

AU - Bentsion, Dmitry

AU - Peterson, Richard

AU - Gedye, Craig

AU - Lebrun-Frénay, Christine

AU - Wick, Antje

AU - Curran, Walter

AU - Mehta, Minesh

N1 - You do not currently have access to this article. Subscription prices and ordering ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM) - 24 Hours access

PY - 2019/11/11

Y1 - 2019/11/11

UR - http://academic.oup.com/neuro-oncology/article-pdf/21/Supplement_6/vi17/30632453/noz175.064.pdf

U2 - 10.1093/neuonc/noz175.064

DO - 10.1093/neuonc/noz175.064

M3 - Presentation

T2 - Neuro-oncology

Y2 - 11 November 2019

ER -

ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM)

Conference

Disciplines

Access to Document

Other files and links

Cite this